Hydroquinone

CHEMBL537 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
110.1 g/mol
LogP
0.6
Phase
4

A topical skin-lightening agent used to treat hyperpigmentation conditions such as melasma, age spots, and post-inflammatory hyperpigmentation by inhibiting the enzyme tyrosinase, which is needed for melanin production in the skin. It has also been investigated for antioxidant and other biological properties in research contexts. Long-term or excessive use can paradoxically cause ochronosis, a darkening of the skin.

分子量

110.1100 g/mol

LogP

0.60

TPSA

40.50 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Oc1ccc(O)cc1

InChI

InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H

Molecular Formula

C6H6O2

HBD / HBA

2 / 2

可旋转键数

0

重原子数

8

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A topical skin-lightening agent used to treat hyperpigmentation conditions such as melasma, age spots, and post-inflammatory hyperpigmentation by inhibiting the enzyme tyrosinase, which is needed for melanin production in the skin. It has also been investigated for antioxidant and other biological properties in research contexts. Long-term or excessive use can paradoxically cause ochronosis, a darkening of the skin.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Hydroquinone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL537. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 785. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.